Nilotinib Is More Potent than Imatinib for Treating Plexiform Neurofibroma In Vitro and In Vivo

• Jiang Wei,

  Affiliation Laboratory for Tumor Genetics, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Marcus Freytag,

  Affiliation Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Yvonne Schober,

  Affiliation Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Marburg, Germany

  ⨯
• Wolfgang A. Nockher,

  Affiliation Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Marburg, Germany

  ⨯
• Victor F. Mautner,

  Affiliation Laboratory for Tumor Genetics, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Reinhard E. Friedrich,

  Affiliation Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Paul W. Manley,

  Affiliation Novartis Institute of Biomedical Research, Basel, Switzerland

  ⨯
• Lan Kluwe,

  Affiliations Laboratory for Tumor Genetics, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Andreas Kurtz

  * E-mail: andreas.kurt@charite.de

  Affiliations Berlin Brandenburg Center for Regenerative Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, Seoul National University, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul, Republic of Korea

  ⨯